Skip to main content
. 2016 Oct 4;6:34382. doi: 10.1038/srep34382

Figure 3. Mouse glycoengineered anti-CD20 Abs trigger enhanced Ab-dependent phagocytosis by Kupffer cells in vivo.

Figure 3

A–C) WT or glycoengineered anti-CD20 mAbs (clone18B12) were used to treat WT mice at the indicated doses. (A) B cell depletion efficacy was assessed in blood by flow cytometry at 30 min post-injection. (B) Frozen liver sections were stained using PE-labeled anti-F4/80 Ab and FITC-labeled anti-B220 Ab. B cell phagocytosis by Kupffer cells is highlighted by white circles. Note that only the glycoengineered form of anti-CD20 trigger phagocytosis at low doses. (C) Summary bar charts showing percentages of engulfed B cells for the indicated conditions. Representative of 2–4 independent experiments. Results are shown as mean ± SEM and were compiled from mosaic images of liver sections (3 independent animals) containing > 1000 Kupffer cells.